DPL Platform



SAFEbody™ is our proprietary precision antibody masking technology designed to enable an antibody to bind its target specifically only after conditional activation of the antibody in target tissues. By engineering and developing our antibody therapeutic candidates to selectively activate in the tumor microenvironment, or TME, our SAFEbody technology is designed to improve safety and tolerability of antibody therapeutics while simultaneously maintaining clinical activity. Through this technology, we believe we can provide ourselves and our partners with a solution to on-target off-tumor toxicity, one of the long-lasting challenges with many approved antibody therapeutics.

Precision masking without self-inhibition

SAFEbody allows us to achieve high levels of masking efficiency with no self-inhibition upon activation.

ADG126 uses this SAFEbody technology.